Generic Name: erenumab
Brand Name: Aimovig
Manufacturer: Novartis Pharmaceuticals Canada Inc.
Manufacturer Requested Reimbursement Criteria1: For prevention of migraine in adults who have at least 8 migraine days per month and who have previously failed, are intolerant, or have a contraindication to at least two migraine preventive therapies
Submission Type: New
Project Status: Active
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||April 04, 2019|
CADTH initially posted the call for patient from July 12, 2018 to August 31, 2018. The pending submission was subsequently delayed and CADTH re-posted the call for patient input when the revised filing date was received.
|Patient group input closed||May 27, 2019|
- Patient input submission received from Migraine Canada Migraine Quebec
|Patient input summary sent for review to patient input groups||June 03, 2019|
|Patient group comments on input summary closed||June 10, 2019|
- Patient input summary feedback received
|Submission received||May 02, 2019|
|Submission accepted for review||May 16, 2019|
|Review initiated||May 17, 2019|
|Draft CADTH review report(s) sent to applicant||August 01, 2019|
|Comments from applicant on draft CADTH review report(s) received||August 13, 2019|
|CADTH review team's comments on draft CADTH review report(s) sent to applicant||October 03, 2019|
|Canadian Drug Expert Committee (CDEC) meeting||October 16, 2019|
|CDEC recommendation sent to applicant and drug plans||October 28, 2019|
October 30, 2019